FDA Grants Emergency Use Authorization To Arthritis Drug ‘Actemra’ For Treatment Of Covid-19 Infection
At Market.us News, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us News. We appreciate your support and look forward to continuing to provide valuable insights for our audience.
The FDA has cleared a new medicine for the treatment of Covid-19 infection. The drug is Actemra and mainly used for the treatment of arthritis. It is used to treat various inflammatory conditions. It reduces inflammation in the body. The FDA said that it has granted an emergency use authorization to the medicine. It can be used for the treatment of those patients who are undergoing treatment at hospitals for Covid-19 infection. Actemra can only be administered to patients above two years of age receiving systemic corticosteroids and medical oxygen. The FDA categorically noted that Actemra is not authorized for use in outpatients with Covid-19.
The medicine prevents deterioration of the patient’s condition. It is also helpful in preventing deaths. Besides, it reduces the risk of placing a patient on a ventilator. Clinical trials showed that the drug delivered promising results in the treatment of Covid-19. The death risk was decreased when the drug was given with additional therapies like corticosteroids. The medicine also cuts the hospitalization timings. The FDA, however, said that vaccines are the most important weapon in the fight against Covid-19. It said that vaccines have successfully decreased the number of Covid-19 patients worldwide. Also, vaccines have prevented deaths due to the virus. But providing additional therapies to patients in hospitals is also important to bolster the fight.
According to the FDA, it is a monoclonal antibody. It works by reducing inflammation and increasing metabolism. The medicine is administered to a patient by intravenous infusion. It is a process that is approved by the FDA for the treatment of several inflammatory diseases. Under this process, fluids are directly placed into the bloodstream. The clinical trials noted that the body’s immune system can be hyperactive in Covid-19 infection. This may result in worsening the condition of a patient. Although the drug does not target SARS-COV-2 directly, the FDA’s decision is based on scientific evidence that suggests that it may be effective in treating Covid-19.
Kathleen Kinder
With over 4 years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.
Latest from Author
- A new zoonotic virus Langya has infected over 35 people in China
- What is the prevalence of long COVIDs? What are the differences between studies?
- Harvard Scientists Discover a New Treatment for Diabetes
- Vitamin d is better for more than just people bones. This is how much vitamin d people need every day
- Education experts focus on causes of mental health suffering in schools, push for solutions